DV
Dividend Vision

CGTX — Cognition Therapeutics Inc

Cognition Therapeutics Inc (CGTX)

Total return is -92.1% over the past 4.8 years, 181.2 points behind SPY at 89.1%. Its deepest 1-year drawdown was 81.3%.

Cognition Therapeutics is a clinical-stage biopharmaceutical company discovering and developing small molecule therapeutics for age-related degenerative diseases and central nervous system and retinal disorders. The company's lead candidate, zervimesine, is in Phase 2 clinical trials for Alzheimer's disease, mild cognitive impairment, geographic atrophy, and dementia with Lewy bodies. The company does not currently distribute dividends and appeals to investors seeking exposure to early-stage drug development in neurodegenerative disease treatment.

CGTX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/08/2021
Last close
$1.01
Market cap
$85,989,696
Average volume
506900.0
Beta
1.754
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.23